ALPN-202 With PD-1 Inhibition in Advanced Malignancies
This is a cohort-based, open-label dose escalation and expansion study in adults with advanced solid tumors or lymphoma.
Advanced Solid Tumor|Lymphoma
DRUG: ALPN-202|DRUG: pembrolizumab KEYTRUDAÂ®
Dose-limiting Toxicities (DLTs), Incidence of DLTs, Up to 6 weeks following study day 1|Adverse Events (AEs), Type, incidence, severity, and seriousness of AEs, 30 days after last dose of study drug|Laboratory Abnormalities, Type, incidence, and severity of laboratory abnormalities, Up to 30 days after last dose of study drug
This is a cohort-based, open-label dose escalation and expansion study in adults with advanced solid tumors or lymphoma.